Anti-Glutamate Receptor ab.
NMDA assay will be performed on either serum or CSF, however CSF is the preferred sample. Serum may give an equivocal result if other autoantibodies are present in which case CSF would be required.
4.0mL Red Top, however CSF is preferred
Indirect immunofluorescence on transfected HEK cell line
Serum screened at 1 in 10 & 1 in 100
CSF screened neat.
$380.57 (Exclusive of GST)
Antibodies (in both serum and CSF) can be low or subthreshold in first samples but rise subsequently. We recommend sending further samples with CSF if the diagnostic suspicion remains high.
NMDAR-antibodies are found in patients with behavioural and cognitive problems and seizures. These can commonly progress over time to a movement disorder autonomic fluctuations and coma.
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) antibodies are neuronal surface-directed antibodies.
Since their discovery in 2007 (Dalmau J etal, Ann Neurol), anti-NMDAR antibodies have been shown to be a frequent cause of a severe but treatable form of immune-mediated encephalitis (Titulaer M et al, Lancet Neurol 2013). Anti-NMDAR encephalitis typically evolves from a viral prodrome to a neuropsychiatric presentation (Irani SR et al, Brain 2010). W
While the disease was originally associated with tumours, typically ovarian teratomas, many patients do not have tumours.
Also known as Anti-Glutamate Receptor antibodies
"*" indicates required fields